---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-062766"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2026-05-15T21:00:31+00:00"
generated_at: "2026-05-15T21:03:54.524142+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BrainStorm Q1 net loss $2.1M; cash below $0.2M; NurOwn Phase 3 preparations ongoing

## Summary
- Net loss $2.1M ($0.19 per share) vs $2.9M ($0.45) in Q1 2025; operating loss $2.0M.
- Cash, equivalents, and restricted cash $0.2M at March 31, 2026, down from $0.3M at Dec 31, 2025.
- R&D expense $0.8M (down from $1.3M); G&A expense $1.3M (down from $1.8M).
- Planning Phase 3b ENDURANCE trial of NurOwn for ALS, targeting ~200 patients; BLA submission planned after Part A.
- Raised $2M via two private placements in Feb 2026; stockholders' deficit $11M; accounts payable $7.3M.

## SEC filing metadata
- accession: 0001104659-26-062766
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2026-05-15T21:00:31+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465926062766/0001104659-26-062766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465926062766/tm2614771d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-062766
- JSON: https://secwatch.observer/filing/0001104659-26-062766.json
- Plain text: https://secwatch.observer/filing/0001104659-26-062766.txt

## Key facts
- Earnings Releases
  BRAINSTORM CELL THERAPEUTICS INC. reported the three months ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was approximately $2.1 million, EPS Net loss per share for the three months ended March 31, 2026 and 2025 was $(0.19) and $(0.45), respectively..
  - Period: the three months ended March 31, 2026
  - Net income: Net loss for the three months ended March 31, 2026 was approximately $2.1 million
  - EPS: Net loss per share for the three months ended March 31, 2026 and 2025 was $(0.19) and $(0.45), respectively.
  - Result: reported results
  source text: BrainStorm Cell Therapeutics Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465926062766/0001104659-26-062766-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.